米诺环素治疗年龄相关性黄斑变性地图样萎缩的2期试验:一项非随机对照试验
这项2期前瞻性单臂非随机对照试验纳入37例年龄相关性黄斑变性地图样萎缩患者,先进行9个月导入期,随后口服米诺环素100 mg每日两次治疗3年。主要终点为导入期与治疗期之间眼底自发荧光地图样萎缩面积平方根变化率的差异,结果为-0.03(0.03)mm/年(P=0.39),未显示米诺环素可减缓地图样萎缩扩大。
要点
- 口服米诺环素100 mg每日两次治疗24个月,地图样萎缩扩大率与9个月导入期相比差异为-0.03(0.03)mm/年(P=0.39)。
- 次要终点包括视力变化率差异0.2字母分/月(95%CI -0.4至0.9;P=0.44)和中心凹下视网膜厚度变化率差异0.7 μm/月(95%CI -0.4至1.8;P=0.20),两期之间均无差异。
- 32例参与者共报告129例治疗中出现的不良事件,其中49例(38%)与米诺环素相关,包括促甲状腺激素水平升高(15例)和皮肤色素沉着/变色(8例),无严重或眼部事件。
核心结论
- 在这项2期非随机对照试验中,与导入期相比,口服米诺环素24个月未与地图样萎缩扩大减少相关,主要和次要结局指标观察一致。
- 该剂量的口服米诺环素可能不与年龄相关性黄斑变性地图样萎缩扩大速率减慢相关。
研究设计与样本
- 这是一项2期、前瞻性、单臂、45个月的非随机对照试验,于2016年12月至2023年4月开展。
- 研究从美国国立卫生研究院(马里兰州贝塞斯达)和布里斯托尔眼科医院(英国布里斯托尔)招募年龄相关性黄斑变性地图样萎缩患者,单眼或双眼患病。
- 共纳入37例参与者(平均[SD]年龄74.3[7.6]岁;女性21例[57%]),其中36例开始治疗期。
- 经过9个月导入期后,参与者开始口服米诺环素100 mg每日两次,持续3年。
- 研究数据分析时间为2022年9月至2023年5月。
主要发现
- 研究眼地图样萎缩平方根扩大率在导入期为0.31(0.03)mm/年,在治疗期为0.28(0.02)mm/年。
- 两期扩大率差异的主要结局指标为-0.03(0.03)mm/年(P=0.39)。
- 次要结局指标中,两期变化率平均差异为视力0.2字母分/月(95%CI -0.4至0.9;P=0.44),中心凹下视网膜厚度0.7 μm/月(95%CI -0.4至1.8;P=0.20)。
- 36例开始治疗期的参与者中,21例(58%)完成至少33个月,15例停止治疗(8例主动要求,6例因不良事件/疾病,1例死亡)。
- 32例参与者共报告129例治疗中出现的不良事件,49例(38%)与米诺环素相关,包括促甲状腺激素水平升高(15例)和皮肤色素沉着/变色(8例),无严重或眼部事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Existing therapies to slow geographic atrophy (GA) enlargement in age-related macular degeneration (AMD) have relatively modest anatomic efficacy, require intravitreal administration, and increase the risk of neovascular AMD. Additional therapeutic approaches are desirable. OBJECTIVE: To evaluate the safety and possible anatomic efficacy of oral minocycline, a microglial inhibitor, for the treatment of GA in AMD. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2, prospective, single-arm, 45-month, nonrandomized controlled trial conducted from December 2016 to April 2023. Patients with GA from AMD in 1 or both eyes were recruited from the National Institutes of Health (Bethesda, Maryland) and Bristol Eye Hospital (Bristol, UK). Study data were analyzed from September 2022 to May 2023. INTERVENTION: After a 9-month run-in phase, participants began oral minocycline, 100 mg, twice daily for 3 years. MAIN OUTCOMES AND MEASURES: The primary outcome measure was the difference in rate of change of square root GA area on fundus autofluorescence between the 24-month treatment phase and 9-month run-in phase. RESULTS: Of the 37 participants enrolled (mean [SD] age, 74.3 [7.6] years; 21 female [57%]), 36 initiated the treatment phase. Of these participants, 21 (58%) completed at least 33 months, whereas 15 discontinued treatment (8 by request, 6 for adverse events/illness, and 1 death). Mean (SE) square root GA enlargement rate in study eyes was 0.31 (0.03) mm per year during the run-in phase and 0.28 (0.02) mm per year during the treatment phase. The primary outcome measure of mean (SE) difference in enlargement rates between the 2 phases was -0.03 (0.03) mm per year (P = .39). Similarly, secondary outcome measures of GA enlargement rate showed no differences between the 2 phases. The secondary outcome measures of mean difference in rate of change between 2 phases were 0.2 letter score per month (95% CI, -0.4 to 0.9; P = .44) for visual acuity and 0.7 μm per month (-0.4 to 1.8; P = .20) for subfoveal retinal thickness. Of the 129 treatment-emergent adverse events among 32 participants, 49 (38%) were related to minocycline (with no severe or ocular events), including elevated thyrotropin level (15 participants) and skin hyperpigmentation/discoloration (8 participants). CONCLUSIONS AND RELEVANCE: In this phase 2 nonrandomized controlled trial, oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase. This observation was consistent across primary and secondary outcome measures. Oral minocycline at this dose is likely not associated with slower rate of enlargement of GA in AMD.
引用
- Keenan TDL, Bailey C, Abraham M, et al. Phase 2 Trial Evaluating Minocycline for Geographic Atrophy in Age-Related Macular Degeneration: A Nonrandomized Controlled Trial. JAMA Ophthalmol. 2024. PMID: 38483382. doi:10.1001/jamaophthalmol.2024.0118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。